Previous close | 5.75 |
Open | 5.71 |
Bid | 6.02 x 1000 |
Ask | 6.69 x 800 |
Day's range | 5.50 - 6.53 |
52-week range | 3.08 - 16.42 |
Volume | |
Avg. volume | 349,390 |
Market cap | 267.524M |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.31 |
Earnings date | 26 Feb 2024 - 01 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 23.50 |
Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.
CAMBRIDGE, Mass. & MONTREAL, November 15, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company’s Polθ inhibitor, RP-3467.
CAMBRIDGE, Mass. & MONTREAL, November 09, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.